Clene Net Income Over Time
| CLNN Stock | USD 4.29 0.37 9.44% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Clene Performance and Clene Correlation. Will Biotechnology sector continue expanding? Could Clene diversify its offerings? Factors like these will boost the valuation of Clene. Projected growth potential of Clene fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Clene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.614 | Earnings Share (3.44) | Revenue Per Share | Quarterly Revenue Growth (0.83) | Return On Assets |
Understanding Clene Inc requires distinguishing between market price and book value, where the latter reflects Clene's accounting equity. The concept of intrinsic value - what Clene's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Clene's price substantially above or below its fundamental value.
It's important to distinguish between Clene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Clene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Clene's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Clene Inc and related stocks such as MacroGenics, Ovid Therapeutics, and Coya Therapeutics Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MGNX | 6.7 M | 6.7 M | 8.4 M | (260.8 K) | (38.3 M) | (20.1 M) | (58.5 M) | (19.6 M) | (171.5 M) | (151.8 M) | (117.8 M) | (190.9 M) | (120 M) | (9.1 M) | (67 M) | (60.3 M) | (63.3 M) |
| OVID | (447 K) | (447 K) | (447 K) | (447 K) | (447 K) | (13.2 M) | (22.4 M) | (64.8 M) | (52 M) | (59.3 M) | (80.7 M) | 122.8 M | (51.4 M) | (52.3 M) | (26.4 M) | (23.8 M) | (25 M) |
| COYA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.9 M) | (12.2 M) | (8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| ORMP | (50 K) | (1.6 M) | (3.3 M) | (4.2 M) | (5.7 M) | (7.2 M) | (11 M) | (10.5 M) | (12.7 M) | (14.4 M) | (11.5 M) | (22.2 M) | (37.8 M) | 5.5 M | (19.1 M) | (17.2 M) | (16.3 M) |
| WHWK | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (3.5 M) | (110.1 M) | (60.5 M) | (65.8 M) | (63.7 M) | (57.3 M) | (60.2 M) |
| CNTX | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (24.6 M) | (7.5 M) | (7.5 M) | 6.6 M | (10.5 M) | (14.8 M) | (24 M) | (26.7 M) | (30.7 M) | (32.3 M) |
| ZNTL | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (45.7 M) | (117.8 M) | (158.7 M) | (236.8 M) | (292.2 M) | (165.8 M) | (149.3 M) | (156.7 M) |
| STTK | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (24 M) | (35.4 M) | (45 M) | (100.6 M) | (87.3 M) | (75.4 M) | (67.9 M) | (71.3 M) |
| PLRX | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (30.3 M) | (631 K) | (39.7 M) | (17.9 M) | (123.3 M) | (161.3 M) | (210.3 M) | (189.3 M) | (179.8 M) |
| CNTB | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (120.3 M) | (205.2 M) | (116.4 M) | (59.5 M) | (15.6 M) | (18 M) | (18.9 M) |
Clene Inc and related stocks such as MacroGenics, Ovid Therapeutics, and Coya Therapeutics Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Clene Inc financial statement analysis. It represents the amount of money remaining after all of Clene Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Clene Inc | CLNN |
Specialization | Consumer Defensive, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 6550 South Millrock |
| Exchange | NASDAQ Exchange |
USD 4.29
Check out Clene Performance and Clene Correlation. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Clene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.